Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
ALK2 / ACVR1 Antibody (Internal)
Goat Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC-P, E |
|---|---|
| Primary Accession | Q04771 |
| Reactivity | Human, Mouse, Rat, Rabbit, Monkey, Pig, Horse, Bovine, Dog |
| Host | Goat |
| Clonality | Polyclonal |
| Calculated MW | 57kDa |
| Dilution | ELISA (1:128000), IHC-P (4 µg/ml), WB (0.3-1 µg/ml) |
| Gene ID | 90 |
|---|---|
| Other Names | Activin receptor type-1, 2.7.11.30, Activin receptor type I, ACTR-I, Activin receptor-like kinase 2, ALK-2, Serine/threonine-protein kinase receptor R1, SKR1, TGF-B superfamily receptor type I, TSR-I, ACVR1, ACVRLK2 |
| Target/Specificity | Human ACVR1 / ALK2. |
| Reconstitution & Storage | Store at -20°C. Minimize freezing and thawing. |
| Precautions | ALK2 / ACVR1 Antibody (Internal) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | ACVR1 |
|---|---|
| Synonyms | ACVRLK2 |
| Function | Bone morphogenetic protein (BMP) type I receptor that is involved in a wide variety of biological processes, including bone, heart, cartilage, nervous, and reproductive system development and regulation (PubMed:20628059, PubMed:22977237). As a type I receptor, forms heterotetrameric receptor complexes with the type II receptors AMHR2, ACVR2A or ACVR2B (PubMed:17911401). Upon binding of ligands such as BMP7 or GDF2/BMP9 to the heteromeric complexes, type II receptors transphosphorylate ACVR1 intracellular domain (PubMed:25354296). In turn, ACVR1 kinase domain is activated and subsequently phosphorylates SMAD1/5/8 proteins that transduce the signal (PubMed:9748228). In addition to its role in mediating BMP pathway-specific signaling, suppresses TGFbeta/activin pathway signaling by interfering with the binding of activin to its type II receptor (PubMed:17911401). Besides canonical SMAD signaling, can activate non-canonical pathways such as p38 mitogen-activated protein kinases/MAPKs (By similarity). May promote the expression of HAMP, potentially via its interaction with BMP6 (By similarity). |
| Cellular Location | Membrane; Single-pass type I membrane protein. |
| Tissue Location | Expressed in normal parenchymal cells, endothelial cells, fibroblasts and tumor-derived epithelial cells |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin. May be involved for left-right pattern formation during embryogenesis (By similarity).
References
Matsuzaki K.,et al.J. Biol. Chem. 268:12719-12723(1993).
ten Dijke P.,et al.Oncogene 8:2879-2887(1993).
Oppermann F.S.,et al.Mol. Cell. Proteomics 8:1751-1764(2009).
Umasankar P.K.,et al.Nat. Cell Biol. 14:488-501(2012).
Shore E.M.,et al.Nat. Genet. 38:525-527(2006).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
